AstraZeneca, MSD present final results of key secondary OS endpoint from phase III PROpel trial at ASCO GU cancers symposium
Results from the final prespecified overall survival (OS) analysis of the PROpel phase III trial in metastatic castration-resistant prostate cancer (mCRPC) showed AstraZeneca and MSD
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!